How Often Do You Really Have to See Patients on Warfarin?

Kuritzky, Louis
October 2011
Internal Medicine Alert;10/15/2011 Supplement 2, p151
The article presents information on a study conducted by researcher A. J. Rose on a large population of persons receiving anticoagulation in the U.S.


Related Articles

  • How Often Do You Really Have to See Patients on Warfarin? Kuritzky, Louis // OB/GYN Clinical Alert;Nov2011 Clinical Briefs in Primary, p21 

    The article discusses research by A. J. Rose et al, published in a 2011 issue of "Chest" on whether patients might be allowed longer intervals without risking either toxicity of supratherapeutic warfarin dose or thrombotic risk of subtherapeutic levels.

  • Trial stopped after antithrombotic excels in preventing post-angioplasty death, MI.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p14 

    Reports on the performance of abciximab at the clinical trials regarding the safety of its use as an antithrombotic agent. Mechanism of action of the drug; Merits of the drug; Comments from the researchers.

  • Pravastatin: Interaction with oral anticoagulant? Trenque, Thierry; Choisy, Henri // BMJ: British Medical Journal (International Edition);4/6/96, Vol. 312 Issue 7035, p886 

    Presents the case of a 64 year old woman who was diagnosed with atrial fibrillation secondary to an adverse effect caused by the interaction of Pravastatin with an oral anticoagulant. Physiological effect of Pravastatin; Caution in the administration of Pravastatin simultaneous to anticoagulant...

  • Anti-anticoagulation. H.D.B. // Cortlandt Forum;10/25/97, Vol. 10 Issue 10, p108 

    Focuses on the anticoagulant Coumadin that represents an increased risk for complications in an 80-year-old woman with a history of falling. Production of intracranial bleeding due to additional falls while on Coumadin.

  • Wide victory for arteries. Munson, Marty; Higbee, Beth // Prevention;Aug94, Vol. 46 Issue 8, p44 

    Discusses CentroRx, a new clot-blocking drug that may help angioplasty be more effective, and the `first drug ever shown to reduce restenosis and the need for repeat procedures. The drug's lack of some of the side effects in the stomach that aspirin might cause; Risk of bleeding; Other possible...

  • Altering anticoagulation therapy: A survey of physicians.  // Journal of the American Dental Association (JADA);May96, Vol. 127 Issue 5, p666 

    Presents a multiple choice quiz on altering anticoagulation therapy, a survey of physicians. Answers.

  • The new-and improved-anticoagulation regimens. Whieldon, David // Patient Care;12/15/1995, Vol. 29 Issue 20, p31 

    Presents information on anticoagulation regimens. Changes in anticoagulant therapy on the way; What anticoagulation is effective for; Use of heparin for most thromboembolic problems; Candidates for testing for underlying hypercoagulation state; More. INSETS: Whither anticoagulation?.;Heparin...

  • Post-approval adverse events of new and old anticoagulants. Hoffman, Keith B.; Demakas, Andrea; Erdman, Colin B.; Dimbil, Mo // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p23 

    A letter to the editor is presented which discusses the inaccuracy on the general safety of the anticoagulant drug dabigatran.

  • Safety of new anticoagulants in high risk patients. Dalgleish, Stephen // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p23 

    A letter to the editor is presented which discusses the safety of new anticoagulants such as rivaroxaban and dabigatran to high-risk patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics